Thursday, September 29, 2016 4:18:28 PM
Tariff has stated that earnings from BENDEKA are highly predictable for at least the next 3.5 years. So if we low ball that number at $30 million in revenue royalties from TEVA we get $420 million. So lets add in Eagles cash of roughly $127 million and we get $547 million
Also, over that time lets add $5 million a quarter in revenue from Ryanodex MH and the rest of Eagles's niche drugs, we get a total of $70 million
Over the next 3.5 years Eagle's cash and revenue value will equal roughly $617 million
So if we subtract that from Eagle's market cap of $1.1 billion we get an EV of $483 million for the rest of Eagle's pipeline which includes all sales from Bendeka and Ryanodex after 3.5 years. Pretty cheap if you ask me.
Thoughts or comments welcomed
P.S. go easy, I'm an amateur
Recent EGRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:49:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 09:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:35:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 01:23:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:44:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:09:16 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/14/2024 10:09:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 08:53:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:50:12 PM
- Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX • PR Newswire (US) • 02/09/2024 10:45:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/07/2024 02:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 10:09:59 PM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 02/02/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 01/26/2024 10:45:00 AM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 01/19/2024 10:45:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 11:56:43 AM
- Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio • GlobeNewswire Inc. • 01/18/2024 11:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 12:00:35 PM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 01/12/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 10:01:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 10:00:02 PM
- The Gross Law Firm Notifies Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 9, 2024 - (NASDAQ: EGRX) • PR Newswire (US) • 01/05/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/23/2023 12:00:19 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM